ASX:NC6Nanollose Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nanollose Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume516,254 shsAverage VolumeN/AMarket Capitalization$6.38 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plant-free viscose-rayon fibre; and a commercial supply chain of microbial cellulose from various waste streams. Its products are used in textile, clothing, and other industries. Nanollose Limited has a collaborative research agreement with Umeå University, MoRe Research, and RISE Processum. The company was founded in 2014 and is based in Nedlands, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Nanollose. Previous Next 2.3 Community Rank Outperform VotesNanollose has received 12 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNanollose has received 14 “underperform” votes. (Add your “underperform” vote.)Community SentimentNanollose has received 53.85% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nanollose and other stocks. Vote “Outperform” if you believe NC6 will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NC6 will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNanollose does not currently pay a dividend.Dividend GrowthNanollose does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nanollose insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Nanollose is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nanollose is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:NC6 Previous Symbol CUSIPN/A CIKN/A Webwww.nanollose.com Phone61 8 9389 3120Debt Debt-to-Equity Ratio8.41 Current Ratio5.20 Quick Ratio5.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$697,693.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.15 Book ValueA$0.01 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares75,000,000Market Cap$6.38 million Next Earnings DateN/A OptionableNot Optionable Receive NC6 News and Ratings via Email Sign-up to receive the latest news and ratings for NC6 and its competitors with MarketBeat's FREE daily newsletter. Nanollose (ASX:NC6) Frequently Asked Questions Has Nanollose been receiving favorable news coverage? Media stories about NC6 stock have trended negative on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nanollose earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Nanollose. Who are some of Nanollose's key competitors? Some companies that are related to Nanollose include Fusion Antibodies (FAB), Bio-Gene Technology (BGT), Tissue Regenix Group (TRX), NovaBay Pharmaceuticals (NBY), Oragenics (OGEN), Bionomics (BNO), Hemogenyx Pharmaceuticals (HEMO), ImmuPharma (IMM), Acrux (ACR), Quest PharmaTech (QPT), Ceapro (CZO), Skinbiotherapeutics (SBTX), Actinogen Medical (ACW), Exopharm (EX1) and AorTech International (AOR). View all competitors. Who are Nanollose's key executives? Nanollose's management team includes the following people: Dr. Wayne Morris Best, Exec. ChairmanMr. Raffaele Germano, CEO, MD & DirectorMr. Gary Cass, Exec. Director of R&D and Exec. DirectorMs. Erlyn Saromines Dale A.C.I.S., B.Com., BCom., GradDipACG, AGIA, ACIS, Company Sec. What is Nanollose's stock symbol? Nanollose trades on the ASX under the ticker symbol "NC6." How big of a company is Nanollose? Nanollose has a market capitalization of $0.00 and generates $697,693.00 in revenue each year. What is Nanollose's official website? The official website for Nanollose is www.nanollose.com. How can I contact Nanollose? The company can be reached via phone at 61 8 9389 3120. This page was last updated on 7/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
